Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 280

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease

Farlow, Martin, Arnold, Steven E., van Dyck, Christopher H., Aisen, Paul S., Snider, B. Joy, Porsteinsson, Anton P., Friedrich, Stuart, Dean, Robert A., Gonzales, Celedon, Sethuraman, Gopalan, DeMattos, Ronald B., Mohs, Richard, Paul, Steven M., Siemers, Eric R.·2012·Alzheimer's & Dementia

Abstract

Objectives: To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of 12 weekly infusions of solanezumab, an anti‐β‐amyloid (Aβ) antibody, in patients with mild‐to‐moderate Alzheimer's disease. Cognitive measures were also obtained. Methods: In this phase 2, randomized, double‐blind, placebo‐controlled clinical trial, 52 patients with Alzheimer's disease received placebo or antibody (100 mg every 4 weeks, 100 mg weekly, 400 mg every 4 weeks, or 400 mg weekly) for 12 weeks. Safety and biomarker evaluations continued until 1 year after randomization. Both magnetic resonance imaging and cerebrospinal fluid (CSF) examinations were conducted at baseline and after the active treatment period. The Aβ concentrations were measured in plasma and CSF, and the Alzheimer's Disease Assessment Scale–cognitive portion was administered. Results: Clinical laboratory values, CSF cell counts, and magnetic resonance imaging scans were unchanged by treatment, and no adverse events could be clearly related to antibody administration. Total (bound to antibody and unbound) Aβ 1–40 and Aβ 1–42 in plasma increased in a dose‐dependent manner. Antibody treatment similarly increased total Aβ 1–40 and Aβ 1–42 in CSF. For patients taking 400 mg weekly, antibody treatment decreased unbound Aβ 1–40 in CSF (P < .01), but increased unbound Aβ 1–42 in CSF in a dose‐dependent manner. The Alzheimer's Disease Assessment Scale–cognitive portion was unchanged after the 12‐week antibody administration. Conclusions: Antibody administration was well tolerated with doses up to 400 mg weekly. The dose‐dependent increase in unbound CSF Aβ 1–42 suggests that this antibody may shift Aβ equilibria sufficiently to mobilize Aβ 1–42 from amyloid plaques.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2011.09.224

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 280

Metadata

Authors
Farlow, M., Arnold, S. E., van Dyck, C. H., Aisen, P. S., Snider, B. J., Porsteinsson, A. P., Friedrich, S., Dean, R. A., Gonzales, C., Sethuraman, G., DeMattos, R. B., Mohs, R., Paul, S. M., & Siemers, E. R.
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2012-06-07
Volume
8
Issue
4
Pages
261-271
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W2001436176
Cited by
280
References
33
FWCI
18.49
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.jalz.2011.09.224
The paper
Farlow, M., Arnold, S. E., van Dyck, C. H., Aisen, P. S., Snider, B. J., Porsteinsson, A. P., Friedrich, S., Dean, R. A., Gonzales, C., Sethuraman, G., DeMattos, R. B., Mohs, R., Paul, S. M., & Siemers, E. R. (2012). Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2011.09.224

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.